Cargando…

Human Relaxin‐2 Fusion Protein Treatment Prevents and Reverses Isoproterenol‐Induced Hypertrophy and Fibrosis in Mouse Heart

BACKGROUND: Heart failure is one of the leading causes of death in Western countries, and there is a need for new therapeutic approaches. Relaxin‐2 is a peptide hormone that mediates pleiotropic cardiovascular effects, including antifibrotic, angiogenic, vasodilatory, antiapoptotic, and anti‐inflamm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Junhui, Hao, Weidong, Fillmore, Natasha, Ma, Hanley, Springer, Danielle, Yu, Zu‐Xi, Sadowska, Agnieszka, Garcia, Andrew, Chen, Ruoyan, Muniz‐Medina, Vanessa, Rosenthal, Kim, Lin, Jia, Kuruvilla, Denison, Osbourn, Jane, Karathanasis, Sotirios K., Walker, Jill, Murphy, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951077/ https://www.ncbi.nlm.nih.gov/pubmed/31818212 http://dx.doi.org/10.1161/JAHA.119.013465

Ejemplares similares

Cardiac specific knock-down of peroxisome proliferator activated receptor α prevents fasting-induced cardiac lipid accumulation and reduces perilipin 2
por: Fillmore, Natasha, et al.
Publicado: (2022)

Circular RNA expression in isoproterenol hydrochloride-induced cardiac hypertrophy
por: Yang, Ming-Hui, et al.
Publicado: (2020)

Carbamazepine alone and in combination with doxycycline attenuates isoproterenol-induced cardiac hypertrophy
por: Errami, Mounir, et al.
Publicado: (2010)

Combinational effect of resveratrol and atorvastatin on isoproterenol-induced cardiac hypertrophy in rats
por: Chakraborty, Songjukta, et al.
Publicado: (2015)

Relaxin'
Publicado: (1983)

Relaxin
por: DeCherney, Alan H.
Publicado: (1982)

A Systems Biology Approach to Investigating Sex Differences in Cardiac Hypertrophy
por: Harrington, Josephine, et al.
Publicado: (2017)

Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol
por: Cai, Lin, et al.
Publicado: (2017)

The Expression of microRNA in Adult Rat Heart with Isoproterenol-Induced Cardiac Hypertrophy
por: Gan, Mailin, et al.
Publicado: (2020)

Syringic acid mitigates isoproterenol‐induced cardiac hypertrophy and fibrosis by downregulating Ereg
por: Han, Xiongyi, et al.
Publicado: (2022)

Relaxin ameliorates high glucose-induced cardiomyocyte hypertrophy and apoptosis via the Notch1 pathway
por: Wei, Xiao, et al.
Publicado: (2018)

Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway
por: Al-rasheed, Nouf M, et al.
Publicado: (2015)

Hydrogen (H(2)) Inhibits Isoproterenol-Induced Cardiac Hypertrophy via Antioxidative Pathways
por: Zhang, Yaxing, et al.
Publicado: (2016)

Palmatine attenuates isoproterenol-induced pathological hypertrophy via selectively inhibiting HDAC2 in rats
por: Yuan, Yonggang, et al.
Publicado: (2017)

Cymbopogon Proximus Essential Oil Protects Rats against Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis
por: Althurwi, Hassan N., et al.
Publicado: (2020)

Amlexanox and Forskolin Prevents Isoproterenol-Induced Cardiomyopathy by Subduing Cardiomyocyte Hypertrophy and Maladaptive Inflammatory Responses
por: Adzika, Gabriel Komla, et al.
Publicado: (2021)

Identification of serum predictors of n-acetyl-l-cysteine and isoproterenol induced remodelling in cardiac hypertrophy
por: KUBERAPANDIAN, Dharaniyambigai, et al.
Publicado: (2021)

Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure
por: Galindo, Cristi L, et al.
Publicado: (2009)

A proteomic view of isoproterenol induced cardiac hypertrophy: Prohibitin identified as a potential biomarker in rats
por: Chowdhury, Debabrata, et al.
Publicado: (2013)

miR-139-5p inhibits isoproterenol-induced cardiac hypertrophy by targetting c-Jun
por: Ming, Su, et al.
Publicado: (2018)

Allylmethylsulfide, a Sulfur Compound Derived from Garlic, Attenuates Isoproterenol-Induced Cardiac Hypertrophy in Rats
por: Mohammed, Soheb Anwar, et al.
Publicado: (2020)

Dendrobium candidum aqueous extract attenuates isoproterenol-induced cardiac hypertrophy through the ERK signalling pathway
por: Cao, Yuan-Yuan, et al.
Publicado: (2020)

Difluoromethylornithine attenuates isoproterenol-induced cardiac hypertrophy by regulating apoptosis, autophagy and the mitochondria-associated membranes pathway
por: Zhao, Yu, et al.
Publicado: (2021)

Puerarin attenuates isoproterenol-induced myocardial hypertrophy via inhibition of the Wnt/β-catenin signaling pathway
por: Wang, Xiaoying, et al.
Publicado: (2022)

Effectual Endeavors of Silk Protein Sericin against Isoproterenol Induced Cardiac Toxicity and Hypertrophy in Wistar Rats
por: Ahsan, Farogh, et al.
Publicado: (2022)

The effect of relaxin on the musculoskeletal system
por: Dehghan, F, et al.
Publicado: (2014)

Characterizing relaxin receptor expression and exploring relaxin’s effect on tissue remodeling/fibrosis in the human bladder
por: Diaz, Edward C., et al.
Publicado: (2020)

Exogenous Hydrogen Sulfide Supplement Attenuates Isoproterenol-Induced Myocardial Hypertrophy in a Sirtuin 3-Dependent Manner
por: Zhang, Jingyao, et al.
Publicado: (2018)

Signaling via the Interleukin-10 Receptor Attenuates Cardiac Hypertrophy in Mice During Pressure Overload, but not Isoproterenol Infusion
por: Stafford, Nicholas, et al.
Publicado: (2020)

Analysis of Therapeutic Targets of A Novel Peptide Athycaltide-1 in the Treatment of Isoproterenol-Induced Pathological Myocardial Hypertrophy
por: Zheng, Xi, et al.
Publicado: (2022)

Relaxin-3 stimulates the hypothalamic-pituitary-gonadal axis
por: McGowan, B. M., et al.
Publicado: (2008)

Evolution of the relaxin-like peptide family
por: Wilkinson, Tracey N, et al.
Publicado: (2005)

Rapamycin Attenuated Cardiac Hypertrophy Induced by Isoproterenol and Maintained Energy Homeostasis via Inhibiting NF-κB Activation
por: Chen, Xi, et al.
Publicado: (2014)

Toll-Like Receptor 4 Inhibition Improves Oxidative Stress and Mitochondrial Health in Isoproterenol-Induced Cardiac Hypertrophy in Rats
por: Katare, Parmeshwar B., et al.
Publicado: (2017)

Targeting the Nrf2/ARE Signalling Pathway to Mitigate Isoproterenol-Induced Cardiac Hypertrophy: Plausible Role of Hesperetin in Redox Homeostasis
por: Velusamy, Prema, et al.
Publicado: (2020)

Transcriptomic Validation of the Protective Effects of Aqueous Bark Extract of Terminalia arjuna (Roxb.) on Isoproterenol-Induced Cardiac Hypertrophy in Rats
por: Kumar, Gaurav, et al.
Publicado: (2019)

Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway
por: Zhao, Tingwei, et al.
Publicado: (2021)

Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ
por: Li, Hongming, et al.
Publicado: (2023)

Distinct activation modes of the Relaxin Family Peptide Receptor 2 in response to insulin-like peptide 3 and relaxin
por: Bruell, Shoni, et al.
Publicado: (2017)

Characterization of relaxin 3 and its receptors in chicken: Evidence for relaxin 3 acting as a novel pituitary hormone
por: Lv, Can, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p1bjdb57d4876jeaurtuhbu9bh